GBS Inc. is on a mission to put the power of non-invasive, real-time diagnostic testing in the hands of patients and their primary health practitioners at point of care. With the world-first Biosensor Platform, GBS Inc. is developing and launching diagnostic tests urgently needed to help eradicate COVID-19 and change the lives of people living with diabetes.
Toll-Free (US & Canada): 800-450-6837
Conference Call Details: International: 857-999-9155
Conference ID: 3678032
Important Information for Voting Shares Online
Shareholders of record with Internet access may submit proxies until 11:59 p.m., Eastern Time, on June 15, 2022, by following the instructions on your proxy cards or at https://www.cstproxy.com/gbs/2022/